


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
FUJIMOTO ET AL.

APPLICATION NO: 09/139,254

FILED: AUGUST 25, 1998

FOR: CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND
DERIVATIVES



Art Unit: 1613

Examiner: R. Gerstl

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
FOR CONTINUED PROSECUTION APPLICATION

Sir:

This paper is being filed within three months of the filing date of the CPA application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached PTO-1449 forms.


Copies of these references are enclosed herewith.

In addition to Yamazaki et al. (EP 865,788 and U.S. 5,958,978) already of record, these references relate to the effect of diclofenac, namely o-(2,6-dichloroanilino)phenylacetic acid, on cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2).

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6926



Norbert Gruenfeld
Agent for Applicants
Reg. No. 30,061

Date: August 14, 2000